Benefits and safety of candesartan treatment in heart failure are independent of age: Insights from the Candesartan in heart failure - Assessment of reduction in mortality and morbidity programme

European Heart Journal

Volumn 29, Issue 24, 2008, Pages 3022-3028

  Cohen Solal, Alain ^a   McMurray, John J V ^b   Swedberg, Karl ^c   Pfeffer, Marc A ^d   Puu, Margareta ^e   Solomon, Scott D ^d   Michelson, Eric L ^f   Yusuf, Salim ^g   Granger, Christopher B ^h  

^a HÔPITAL LARIBOISIÈRE   (France)

^b WESTERN INFIRMARY   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

^g MCMASTER UNIVERSITY   (Canada)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adverse events; Age; Candesartan; Dose; Heart failure; Hospitalization; Mortality

Indexed keywords

CANDESARTAN; PLACEBO;

ADULT; AGED; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 58049191438     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn476     Document Type: Article

References (13)

1. Kannel WB. Current status of the epidemiology of heart failure. Curr Cardiol Rep 1999;1:11-19.
2. Task force for the diagnosis and treatment of chronic heart failure ESoC. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
3. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360:1631-1639.
4. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
5. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev 1993;73:413-467.
6. Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004;6:663- 668.
7. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev 2002;7:9-16.
8. Maison P, Cunin P, Hemery F, Fric F, Elie N, Del'volgo A, Dubois-Rande JL, Hittinger L, Macquin-Mavier I. Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study. Eur J Clin Pharmacol 2005;61:445-451.
9. Hulsmann M, Berger R, Mortl D, Pacher R. Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey. Eur J Heart Fail 2005;7:657-661.
10. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003;362:759-766.
11. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail 1999;5:276-282.
12. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75.
13. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551.